Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Zogenix Inc. Shares Swooned

By Sean Williams - Mar 6, 2014 at 2:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Zogenix shares falter after the company reports disappointing fourth-quarter results. Find out what investors should really have their eyes on instead.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Zogenix ( ZGNX -4.97% ), a biopharmaceutical company focused on developing therapies to treat central nervous system disorders and pain, dipped by as much as 13% after the company reported worse than expected fourth-quarter results after the closing bell last night.

So what: For the quarter, Zogenix reported a modest increase in revenue to $9.9 million, from $9.5 million in the year-ago period. Sumavel DosePro, the company's FDA-approved rapid-acting migraine medication, provided $9 million in revenue, with service and other revenue accounting for the other $0.9 million. The company's adjusted net loss shrunk on an earnings-per-share basis to $0.13 from $0.16 due to more shares now outstanding, but actually delivered a widening in its net loss of 4% compared to this quarter last year. By comparison, Wall Street had expected a narrower quarterly loss of just $0.09 per share.

Now what: These results were pretty much par for the course as Sumavel DosePro sales growth has been unimpressive for multiple quarters now. The real allure for Zogenix comes from Zohydro ER, its severe pain therapy that was approved in October and first made available in select pharmacies this week. The Food and Drug Administration is quite fickle with severe pain med approvals, so this was a bit of a surprise that could go a long way to getting Zogenix toward profitability. If all goes well, Zogenix may be profitable by 2015, but given that its shares have vaulted higher by more than 200% since September, much of that optimism may already be baked into the share price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
ZGNX
$11.85 (-4.97%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.